JP2024524554A - ピエゾ型機械受容イオンチャネル成分1(piezo1)アゴニストによる静脈瘤の処置 - Google Patents

ピエゾ型機械受容イオンチャネル成分1(piezo1)アゴニストによる静脈瘤の処置 Download PDF

Info

Publication number
JP2024524554A
JP2024524554A JP2024500281A JP2024500281A JP2024524554A JP 2024524554 A JP2024524554 A JP 2024524554A JP 2024500281 A JP2024500281 A JP 2024500281A JP 2024500281 A JP2024500281 A JP 2024500281A JP 2024524554 A JP2024524554 A JP 2024524554A
Authority
JP
Japan
Prior art keywords
seq
complement
position corresponding
thymine
uracil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524554A5 (https=
Inventor
アレン レベズ フェレイラ、マヌエル
バックマン、ジョシュア
リー、アレクサンダー
バラス、アリス
アベカシス、ゴンサロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2024524554A publication Critical patent/JP2024524554A/ja
Publication of JP2024524554A5 publication Critical patent/JP2024524554A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024500281A 2021-07-08 2022-07-05 ピエゾ型機械受容イオンチャネル成分1(piezo1)アゴニストによる静脈瘤の処置 Pending JP2024524554A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163219462P 2021-07-08 2021-07-08
US63/219,462 2021-07-08
PCT/US2022/073441 WO2023283560A1 (en) 2021-07-08 2022-07-05 Treatment of varicose veins with piezo type mechanosensitive ion channel component 1 (piezo1) agonists

Publications (2)

Publication Number Publication Date
JP2024524554A true JP2024524554A (ja) 2024-07-05
JP2024524554A5 JP2024524554A5 (https=) 2025-06-26

Family

ID=82748409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500281A Pending JP2024524554A (ja) 2021-07-08 2022-07-05 ピエゾ型機械受容イオンチャネル成分1(piezo1)アゴニストによる静脈瘤の処置

Country Status (10)

Country Link
US (1) US20230041060A1 (https=)
EP (1) EP4367266A1 (https=)
JP (1) JP2024524554A (https=)
KR (1) KR20240049797A (https=)
CN (1) CN121175436A (https=)
AU (1) AU2022307546A1 (https=)
CA (1) CA3225855A1 (https=)
IL (1) IL309694A (https=)
MX (1) MX2023015276A (https=)
WO (1) WO2023283560A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4317456T3 (da) * 2019-02-18 2025-09-08 Regeneron Pharma Varianter af mekanoensitiv ionkanalkomponent 1 af piezotypen (piezo1) og anvendelser deraf

Also Published As

Publication number Publication date
WO2023283560A1 (en) 2023-01-12
CA3225855A1 (en) 2023-01-12
MX2023015276A (es) 2024-04-03
EP4367266A1 (en) 2024-05-15
AU2022307546A1 (en) 2024-01-04
IL309694A (en) 2024-02-01
CN121175436A (zh) 2025-12-19
US20230041060A1 (en) 2023-02-09
KR20240049797A (ko) 2024-04-17

Similar Documents

Publication Publication Date Title
US20260078378A1 (en) Treatment Of Sepsis With PCSK9 And LDLR Modulators
US20240102013A1 (en) Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors
US20230000897A1 (en) Treatment Of Cerebrovascular Disease With Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) Agents
JP2024524554A (ja) ピエゾ型機械受容イオンチャネル成分1(piezo1)アゴニストによる静脈瘤の処置
WO2020257758A1 (en) Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors
US12186378B2 (en) Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists
EP4114975B1 (en) Fascin-2 (fscn2) variant and use thereof
US20210371930A1 (en) Solute Carrier Family 26 Member 5 (SLC26A5) Variants And Uses Thereof
US20230034093A1 (en) Treatment Of Cognitive Impairment With Alpha-N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 5 (ST6GALNAC5) Inhibitors
WO2023278694A1 (en) Treatment of hypertension with solute carrier family 9 isoform a3 regulatory factor 2 (slc9a3r2) inhibitors
CA3141309A1 (en) Synaptojanin 2 (synj2) variants and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250618